MSLN and neoplasm: Another therapy intended for use either in combination with a standard anti-tumor modality or as a stand-alone treatment is Isocel, which is an anti-mesothelin CAR γδ T cell therapy that began phase 3 clinical trials during the fourth quarter of 2023 [221].